Skip to content

A multicenter controlled clinical trial on the improvement of sepsis-associated CCI muscular dystrophy by time-sharing administration(Day-3-Night-2) of Huanglian Decoction

A multicenter controlled clinical trial on the improvement of sepsis-associated CCI muscular dystrophy by time-sharing administration(Day-3-Night-2) of Huanglian Decoction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000045
Enrollment
Unknown
Registered
2024-04-16
Start date
2023-09-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-related Chronic Care Illnesses

Interventions

Control Group:Continuous pumping of enteral nutrition solution.
Huanglian Decoction Control Group:" Day 3 Night 2 " method was given enteral nutrition solution.Nasal feeding was not given at other time points. Huanglian Decoction was given at regular time.
Observation Group:"Day 3 Night 2" method of administration of enteral nutritional solution. Nasal gavage was not given at other time points.
Huanglian Decoction Group:Enteral nutrient solution was given by the method of"Day 3 Night 2".Huanglian Decoction was given at the same time as the enteral nutrient solution. Nasogastric feeds were no

Sponsors

Jiangsu Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1) Those who met the diagnostic criteria of sepsis-related CCI. 2) Age between 18 and 85 years old, gender is not limited. 3) Receive enteral nutrition therapy. 4)No serious metabolic disease and other diseases of the digestive tract, such as radiation enteritis and broken bowel syndrome. 5) Informed consent and volunteer to be tested.

Exclusion criteria

Exclusion criteria: Exclusion Criteria 1) ICU stay less than 14 days. 2) Mechanical intestinal obstruction, gastrointestinal hemorrhage. 3) Refusal or inability to perform enteral nutrition therapy. 4) Frequent death or failure of resuscitation, inability to cooperate or refusal to complete the relevant examination. 5) Pregnant and lactating women. 6) Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Thickness of the median femoral, rectus femoris, and tibialis anterior muscles measured by ultrasound, and cross-sectional area of the rectus femoris muscle;Diaphragmatic indicators (thickness, rate of change, mobility) measured by ultrasound;Ultrasound-measured intra-abdominal fat thickness, including subcutaneous and visceral fat thicknesses;

Secondary

MeasureTime frame
28- and 90-day survival rates;NRS2002 score;Serum nutritional indicators: haemoglobin, albumin, prealbumin and testosterone;APACHE II score;SOFA score;NUTRIC score;

Countries

China

Contacts

Public ContactJiang hua

Jiangsu Provincial Hospital of Chinese Medicine

yfy0096@njucm.edu.cn+86 133 8277 4099

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026